Blackstone Injecting $700M Into Merck Cancer Therapy
By Al Barbarino · November 4, 2025, 11:45 AM EST
Merck & Co. said Tuesday it will receive $700 million from Blackstone Life Sciences to help fund development of sacituzumab tirumotecan, an experimental antibody-drug conjugate targeting TROP2, a protein found on...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login